Sidney Kimmel Comprehensive Cancer Center

Johns Hopkins Medicine

Baltimore, MD

Sorting 12 by

Accepting patients

DFV890

A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases
  • NLRP3 Inhibitor
  • Phase 1
  • Has results

Accepting patients

ACCESS

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)
  • Allogeneic Stem Cell Transplant
  • Pre-Transplant
  • Phase 2

Accepting patients

Venetoclax in Combination With ASTX727

Venetoclax in Combination With ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 2

Accepting patients

ARC-T Cells Plus SPRX002

Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome, Including Long-term Safety Follow-up
  • CAR T Cell
  • Phase 1

Accepting patients

Luspatercept and Lenalidomide (L2)

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
  • Erythroid Maturation Agent (EMA)
  • Immunomodulatory Drug
  • Red Blood Cell Stimulant
  • Phase 1/2

Accepting patients

TCR Engineered Donor T-Cells

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
  • T Cell (Allogeneic)
  • Phase 1
  • Has results

Accepting patients

PedAL Screening

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
  • Phase 1/2

Accepting patients

MyeloMATCH Master Protocol

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
  • Genetic Sequencing
  • Phase 2

Accepting patients

SX-682

A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
  • CXCR1 Inhibitor
  • CXCR2 Inhibitor
  • Phase 1
  • Has results

Accepting patients

Itacitinib

Phase 1a/1b Study of Itacitinib (INCB039110) for Cytokine Release Syndrome Prevention and Minimization of Immunosuppression Following Nonmyeloablative Related Partially HLA-mismatched Peripheral Blood Stem Cell Transplant (PBSCT) With High-dose Posttransplantation Cyclophosphamide in Older Patients (Age 60 Years)
  • Allogeneic Stem Cell Transplant
  • JAK1 Inhibitor
  • Phase 1